Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
186RNL for Recurrent Glioma After Prior 186RNL Treatment
NCT05460507Phase 1Recruiting
- Sponsor
- Cerenome
- Start
- Dec 2024
- Primary completion
- Mar 2028
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rhenium-186-obisbemeda in glioma, sponsored by Cerenome. Primary endpoints: Assessment of safety and tolerability of a second dose of 186RNL and Overall Survival at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
rhenium-186-obisbemeda
03
Conditions
glioma
Beyond the preview
Go deeper on NCT05460507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05460507.